Homepage Bottom Left
-
Updated Standards of Care sent for endorsement
Montreal, April 17, 2020 – The Canadian Integrated and Comprehensive Care Standards for Bleeding Disorders have now been finalized and sent to stakeholders for endorsement....
-
Gene Therapy Updates
FDA grants priority review for Biomarin’s hemophilia A gene therapy San Rafael, California, February 21, 2020 – Biomarin Pharmaceuticals has announced that the U.S. Food...
-
Patients’ and caregivers’ “lived experience” crucial in CHS submissions on product access
It’s an exciting time in care for people with bleeding disorders. In recent years, a number of novel therapies have come through clinical trials and...
-
CHS CONTACT takes off!
Here we are at the launch of CHS CONTACT, our new online information platform. This much-anticipated debut coincides with World Hemophilia Day, a day to...
-
No emicizumab this year for non-inhibitor patients
Montreal, April 17, 2020 – The Canadian Hemophilia Society (CHS) has learned that emicizumab (Hemlibra) will not become available for those with hemophilia A without...